In addition, we confirmed PTEN mutations as putative resistance markers in the PIK3CA mutant ovarian serous cystadenocarcinoma cell line TOV-21G, which should have been sensitive to the AKT inhibitor GSK690693 according to its sensitivity biomarker (Figure 1E).29 This evidence concerns the gene PIK3CA and ovarian serous cystadenocarcinoma.